The Value of In Vitro Dissolution in Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Value of In Vitro Dissolution in Drug Development
A Position Paper from the AAPS In Vitro Release and Dissolution Focus Group


Pharmaceutical Technology
Volume 33, Issue 4, pp. 52-64

9. FDA, Guidance for Industry: SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (Rockville, MD, 1997).

10. FDA, Guidance for Industry: Immediate-Release Solid Oral Dosage Forms. Scale-up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (Rockville, MD, 1995).

11. S. Azarmi, W. Roa, and R. Löbenberg, "Current Perspectives in Dissolution Testing of Conventional and Novel Dosage Forms," Int. J. Pharm. 328 (1), 12–21 (2007).

12. W.E. Bowen et al., "A Biopharmaceutical Classification System Approach to Dissolution: Mechanisms and Strategies," in Biopharmaceutics Applications in Drug Development (Springer US, 2008) pp. 290-316.

13. C. Tong et al., "Commentary on AAPS Workshop: Dissolution Testing for the Twenty-first Century: Linking Critical Quality Attributes and Critical Process Parameters to Clinically Relevant Dissolution," Pharm. Res. 24 (9), 1603–1607 (2007).

14. FDA, Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (Rockville, MD, 2000).

15. WHO, "Proposal to Waive In Vivo Bioequivalence Requirements for the WHO Model List of Essential Medicines Immediate Release, Solid Oral Dosage Forms," working document QAS/04.109/Rev.1, 2005.

16. EMEA, "Note for Guidance on the Investigation of Bioavailability and Bioequivalence. European Agency for Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products," (London, England) 2001.

17. E. Rinaki et al., "Identification of Biowaivers Among Class II Drugs: Theoretical Justification and Practical Examples," Pharm. Res. 21 (9), 1567–1572 (2004).

18. M. Yazdanian et al., "The 'High Solubility' Definition of the Current FDA Guidance on Biopharmaceutical Classification System May Be Too Strict for Acidic Drugs," Pharm. Res. 21 (2), 293–299 (2004).

19. FDA, Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products—General Considerations (Rockville, MD, 2003).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here